InSphero completes acquisition of Doppl

We are pleased to announce that our acquisition of Doppl SA, including the Sun Bioscience technology, has officially been completed. This milestone expands our capabilities in human-relevant 3D biology and strengthens the support we offer across preclinical research.

Doppl brings a distinctive organoid technology portfolio featuring tessellated organoid arrays, a leading biobank, and assay solutions designed for reproducibility, efficiency, and high-quality imaging. Combined with InSphero’s scalable spheroid platforms and translational assay expertise, these additions create a more complete ecosystem for researchers working to understand human biology with greater precision.

With organoids and spheroids now available under one roof, scientists gain more flexibility to choose the biology best suited to their question, whether for mechanistic studies, high-content screening, or human-centric translational applications. This step reflects our commitment to advancing predictive in vitro research and supporting the growing need for models that better reflect human physiology.

We are grateful for the trust and partnership of both teams and are energized by the innovation that lies ahead. Together, we are bringing new momentum to the future of 3D biology!